Global Liraglutide Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024

Liraglutide (NN2211) is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion. Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing it in the U.S. under the brand name Saxenda as a treatment for obesity in adults with at least one weight-related comorbid condition. Scope of the Report: The total amount of Patents about Liraglutide are 1871, among those Patents, 44%is about application, 26%is about Combination therapy, and 12%is about Preparation method. In these patents, accounting for Europe is the largest, followed by North America, and finally Asia. The application of Liraglutide Liraglutide for the treatment of type 2 diabetes mellitus Liraglutide 1.2 mg daily in triple therapy regimens (in combination with metformin and a sulphonylurea, or metformin and a thiazolidinedione) is recommended as an option for the treatment of people with type 2 diabetes, only if used as described for exenatide in 'Type 2 diabetes: the management of type 2 diabetes' Liraglutide 1.2 mg daily in dual therapy regimens (in combination with metformin or a sulphonylurea) is recommended as an option for the treatment of people with type 2 diabetes, only if the person is intolerant of either metformin or a sulphonylurea, or treatment with metformin or a sulphonylurea is contraindicated, and the person is intolerant of thiazolidinediones and dipeptidyl peptidase-4 (DPP-4) inh ...
Table of Contents 1 Market Overview 1.1 Liraglutide Introduction 1.2 Market Analysis by Type 1.2.1 Pills 1.2.2 Liquid 1.3 Market Analysis by Applications 1.3.1 Hospital 1.3.2 Drug Store 1.4 Market Analysis by Regions 1.4.1 North America (United States, Canada and Mexico) 1.4.1.1 United States Market States and Outlook (2014-2024) 1.4.1.2 Canada Market States and Outlook (2014-2024) 1.4.1.3 Mexico Market States and Outlook (2014-2024) 1.4.2 Europe (Germany, France, UK, Russia and Italy) 1.4.2.1 Germany Market States and Outlook (2014-2024) 1.4.2.2 France Market States and Outlook (2014-2024) 1.4.2.3 UK Market States and Outlook (2014-2024) 1.4.2.4 Russia Market States and Outlook (2014-2024) 1.4.2.5 Italy Market States and Outlook (2014-2024) 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) ...
2811

1428

OUR CLIENT